BSE Live
Aug 16, 16:01Prev. Close
4262.25
Open Price
4262.00
Bid Price (Qty.)
4296.90 (2)
Offer Price (Qty.)
4300.00 (15)
NSE Live
Aug 16, 15:58Prev. Close
4260.80
Open Price
4275.00
Bid Price (Qty.)
4297.80 (1)
Offer Price (Qty.)
0.00 (0)
Profit & Loss account of Dr Reddys Laboratories (in Rs. Cr.) | Mar 22 | Mar 21 | Mar 20 | Mar 19 | Mar 18 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
INCOME | ||||||
Revenue From Operations [Gross] | 14,315.30 | 13,281.40 | 11,803.00 | 10,572.90 | 9,302.60 | |
Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Revenue From Operations [Net] | 14,315.30 | 13,281.40 | 11,803.00 | 10,572.90 | 9,302.60 | |
Total Operating Revenues | 14,405.20 | 13,349.10 | 11,850.40 | 10,625.50 | 9,359.30 | |
Other Income | 482.00 | 801.10 | 743.20 | 238.40 | 204.00 | |
Total Revenue | 14,887.20 | 14,150.20 | 12,593.60 | 10,863.90 | 9,563.30 | |
EXPENSES | ||||||
Cost Of Materials Consumed | 3,378.40 | 3,266.30 | 2,556.50 | 2,103.20 | 2,011.00 | |
Purchase Of Stock-In Trade | 2,057.10 | 1,252.30 | 1,117.20 | 868.60 | 671.60 | |
Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Changes In Inventories Of FG,WIP And Stock-In Trade | -389.60 | -395.60 | -99.90 | 66.00 | -51.60 | |
Employee Benefit Expenses | 2,434.60 | 2,270.10 | 2,030.20 | 1,931.90 | 1,843.00 | |
Finance Costs | 38.00 | 46.70 | 47.80 | 56.80 | 62.80 | |
Depreciation And Amortisation Expenses | 814.30 | 835.00 | 789.20 | 780.60 | 774.10 | |
Other Expenses | 4,320.80 | 3,804.20 | 3,376.80 | 3,356.10 | 3,555.40 | |
Total Expenses | 12,663.40 | 11,094.00 | 9,817.80 | 9,163.20 | 8,866.30 | |
Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 2,223.80 | 3,056.20 | 2,775.80 | 1,700.70 | 697.00 | |
Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Profit/Loss Before Tax | 2,223.80 | 3,056.20 | 2,775.80 | 1,700.70 | 697.00 | |
Tax Expenses-Continued Operations | ||||||
Current Tax | 392.60 | 540.10 | 483.90 | 281.80 | 138.10 | |
Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Deferred Tax | 208.00 | 329.70 | -645.80 | 141.60 | -8.00 | |
Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Total Tax Expenses | 600.60 | 869.80 | -161.90 | 423.40 | 130.10 | |
Profit/Loss After Tax And Before ExtraOrdinary Items | 1,623.20 | 2,186.40 | 2,937.70 | 1,277.30 | 566.90 | |
Profit/Loss From Continuing Operations | 1,623.20 | 2,186.40 | 2,937.70 | 1,277.30 | 566.90 | |
Profit/Loss For The Period | 1,623.20 | 2,186.40 | 2,937.70 | 1,277.30 | 566.90 | |
OTHER ADDITIONAL INFORMATION | ||||||
EARNINGS PER SHARE | ||||||
Basic EPS (Rs.) | 97.85 | 131.84 | 177.23 | 76.98 | 34.19 | |
Diluted EPS (Rs.) | 97.85 | 131.46 | 176.88 | 76.85 | 34.12 | |
VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
STORES, SPARES AND LOOSE TOOLS | ||||||
Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
Equity Share Dividend | 414.60 | 414.70 | 391.40 | 332.00 | 399.20 | |
Tax On Dividend | 0.00 | 0.00 | 0.00 | 68.20 | 0.00 | |
Equity Dividend Rate (%) | 600.00 | 500.00 | 500.00 | 400.00 | 400.00 |
28.07.2022
Dr Reddys Labs Consolidated June 2022 Net Sales at Rs 5,232.90 crore, up 5.82% Y-o-Y
28.07.2022
Dr Reddys Labs Standalone June 2022 Net Sales at Rs 3,630.60 crore, up 5.74% Y-o-Y
19.05.2022
Dr Reddys Labs Consolidated March 2022 Net Sales at Rs 5,474.90 crore, up 14.82% Y-o-Y
19.05.2022
Dr Reddys Labs Standalone March 2022 Net Sales at Rs 3,668.70 crore, up 9.49% Y-o-Y
27.07.2022
Dr Reddy’s Q1 Results Preview | Profit may rise 47-50%; revenue likely to grow 11-12%
13.07.2022
Dr Reddys Q1 PAT seen up 65.5% YoY to Rs 629.9 cr: ICICI Direct
08.07.2022
Dr Reddys Laboratories Q1 PAT seen up 15.9% YoY to Rs 661.8 cr: Prabhudas Lilladher
28.01.2022
Dr Reddy’s Q3 Preview | Revenue expected to increase 10-15%, PAT likely to grow 22-25%